Details for New Drug Application (NDA): 202103
✉ Email this page to a colleague
The generic ingredient in DASATINIB is dasatinib. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the dasatinib profile page.
Summary for 202103
Tradename: | DASATINIB |
Applicant: | Apotex |
Ingredient: | dasatinib |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 202103
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 20MG | ||||
Approval Date: | Jun 10, 2016 | TE: | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
Approval Date: | Jun 10, 2016 | TE: | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 70MG | ||||
Approval Date: | Jun 10, 2016 | TE: | RLD: | No |
Complete Access Available with Subscription